Regeneron(REGN) Prnewswire·2025-01-23 10:45Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Regeneron Pharmaceuticals, Inc. regarding a class action lawsuit alleging misleading statements and omissions related to the pricing and sales of Eylea, a primary product of the company [1]. Group 1: Allegations - The complaint alleges that Regeneron paid credit card fees to distributors to prevent them from charging Eylea customers more for credit card usage [1]. - These payments effectively subsidized the prices customers paid when using credit cards for Eylea purchases, leading to a price concession that lowered Eylea's selling price [1]. - The price concessions provided Regeneron with a competitive advantage, as retina practices were sensitive to higher prices for anti-VEGF medications [1]. - As a result of these actions, Regeneron reportedly inflated Eylea sales figures and overstated the Average Selling Price (ASP) reported to federal agencies, violating the False Claims Act [1]. Group 2: Class Action Details - The class period for the lawsuit is from November 2, 2023, to October 30, 2024, and shareholders are encouraged to register for participation [1][2]. - The deadline for shareholders to seek lead plaintiff status is March 10, 2025, and there is no cost or obligation to participate in the case [2]. Group 3: Law Firm's Mission - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors affected by deceit and illegal business practices [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [3].